542 related articles for article (PubMed ID: 19333216)
1. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule.
De Gennaro Colonna V; Bianchi M; Pascale V; Ferrario P; Morelli F; Pascale W; Tomasoni L; Turiel M
Med Sci Monit; 2009 Apr; 15(4):RA91-101. PubMed ID: 19333216
[TBL] [Abstract][Full Text] [Related]
2. Association of asymmetric dimethylarginine and endothelial dysfunction.
Böger RH
Clin Chem Lab Med; 2003 Nov; 41(11):1467-72. PubMed ID: 14656027
[TBL] [Abstract][Full Text] [Related]
3. The clinical significance of asymmetric dimethylarginine.
Siroen MP; Teerlink T; Nijveldt RJ; Prins HA; Richir MC; van Leeuwen PA
Annu Rev Nutr; 2006; 26():203-28. PubMed ID: 16848705
[TBL] [Abstract][Full Text] [Related]
4. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor.
Böger RH
J Nutr; 2004 Oct; 134(10 Suppl):2842S-2847S; discussion 2853S. PubMed ID: 15465797
[TBL] [Abstract][Full Text] [Related]
5. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor.
Böger RH
Cardiovasc Res; 2003 Oct; 59(4):824-33. PubMed ID: 14553822
[TBL] [Abstract][Full Text] [Related]
6. Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases.
Böger RH; Bode-Böger SM
Semin Thromb Hemost; 2000; 26(5):539-45. PubMed ID: 11129410
[TBL] [Abstract][Full Text] [Related]
7. The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function.
Richir MC; Bouwman RH; Teerlink T; Siroen MP; de Vries TP; van Leeuwen PA
JPEN J Parenter Enteral Nutr; 2008; 32(6):613-21. PubMed ID: 18974239
[TBL] [Abstract][Full Text] [Related]
8. Increased (E)-4-hydroxy-2-nonenal and asymmetric dimethylarginine concentrations and decreased nitric oxide concentrations in the plasma of patients with major depression.
Selley ML
J Affect Disord; 2004 Jun; 80(2-3):249-56. PubMed ID: 15207938
[TBL] [Abstract][Full Text] [Related]
9. Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA).
Maas R
Vasc Med; 2005 Jul; 10 Suppl 1():S49-57. PubMed ID: 16444869
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelium is the organ chiefly responsible for the catabolism of plasma asymmetric dimethylarginine--an explanation for the elevation of plasma ADMA in disorders characterized by endothelial dysfunction.
McCarty MF
Med Hypotheses; 2004; 63(4):699-708. PubMed ID: 15325021
[TBL] [Abstract][Full Text] [Related]
11. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes.
Yamagishi S; Ueda S; Okuda S
Med Hypotheses; 2007; 69(4):922-4. PubMed ID: 17368960
[TBL] [Abstract][Full Text] [Related]
12. The biochemistry, measurement and current clinical significance of asymmetric dimethylarginine.
Blackwell S
Ann Clin Biochem; 2010 Jan; 47(Pt 1):17-28. PubMed ID: 19940201
[TBL] [Abstract][Full Text] [Related]
13. [Asymmetric dimethylarginine--a novel cardiovascular risk factor].
Siroká R; Cibulka R; Rajdl D; Racek J
Vnitr Lek; 2006 Mar; 52(3):249-55. PubMed ID: 16722156
[TBL] [Abstract][Full Text] [Related]
14. Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets?
Rochette L; Lorin J; Zeller M; Guilland JC; Lorgis L; Cottin Y; Vergely C
Pharmacol Ther; 2013 Dec; 140(3):239-57. PubMed ID: 23859953
[TBL] [Abstract][Full Text] [Related]
15. The biology and therapeutic potential of the DDAH/ADMA pathway.
Arrigoni F; Ahmetaj B; Leiper J
Curr Pharm Des; 2010; 16(37):4089-102. PubMed ID: 21247398
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus infection impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine in transplant arteriosclerosis.
Weis M; Kledal TN; Lin KY; Panchal SN; Gao SZ; Valantine HA; Mocarski ES; Cooke JP
Circulation; 2004 Feb; 109(4):500-5. PubMed ID: 14732750
[TBL] [Abstract][Full Text] [Related]
17. Asymmetric dimethylarginine (ADMA) and other endogenous nitric oxide synthase (NOS) inhibitors as an important cause of vascular insulin resistance.
Toutouzas K; Riga M; Stefanadi E; Stefanadis C
Horm Metab Res; 2008 Sep; 40(9):655-9. PubMed ID: 18792879
[TBL] [Abstract][Full Text] [Related]
18. Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials.
Böger RH
Vasc Med; 2005 Jul; 10 Suppl 1():S19-25. PubMed ID: 16444865
[TBL] [Abstract][Full Text] [Related]
19. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase.
Lin KY; Ito A; Asagami T; Tsao PS; Adimoolam S; Kimoto M; Tsuji H; Reaven GM; Cooke JP
Circulation; 2002 Aug; 106(8):987-92. PubMed ID: 12186805
[TBL] [Abstract][Full Text] [Related]
20. Role of asymmetric dimethylarginine (ADMA) in diabetic vascular complications.
Yamagishi S; Ueda S; Nakamura K; Matsui T; Okuda S
Curr Pharm Des; 2008; 14(25):2613-8. PubMed ID: 18991678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]